From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

If trusted partners in health, including pharmaceutical companies, can tackle the stigma of obesity and GLP-1s head-on with effective patient resources for emotional support and personalised care ...

Both pharma giants have had difficulty producing enough of the drugs to meet demand. And though each saw their stocks soar due to GLP-1s, there is a better way to play the market. Over the past ...

Sanofi now has the go-ahead from the FDA to market the GLP-1 drug in the US. The drug, originally developed by Zealand Pharma, has been available for several years in Europe under the brand name ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Over the last 24 months, the growth we have seen from GLP-1s has been the focal topic for the global pharmaceutical sector and subsequent read-across has had significant traction across the wider ...

ESG Risk Rating and Morningstar Equity Research Valuation for GLP-1 Manufacturers and Entrants Notes: *Altimmune, Inc., Viking Therapeutics, Structure Therapeutics Inc., and Zealand Pharma A/S are ...